Sponsored Links
| Two-Year Data From Phase 2 Trial Of Genzyme's Eliglustat Tartrate For Gaucher Disease To Be Published In The Journal Blood |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |||
|
Genzyme Corporation (NASDAQ: GENZ) announced that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers... Read more: Lymphology/Lymphedema News From Medical News Today
|